UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (121) 121
life sciences & biomedicine (104) 104
humans (90) 90
female (58) 58
oncology (56) 56
male (51) 51
middle aged (46) 46
aged (41) 41
adult (37) 37
cancer (26) 26
research (25) 25
metastasis (18) 18
tumors (18) 18
aged, 80 and over (17) 17
animals (16) 16
genetic aspects (16) 16
genomes (16) 16
medical research (16) 16
patients (16) 16
analysis (15) 15
antineoplastic agents - therapeutic use (15) 15
care and treatment (15) 15
carcinoma, non-small-cell lung - drug therapy (14) 14
medicin och hälsovetenskap (14) 14
polymorphism, single nucleotide (14) 14
studies (14) 14
chemotherapy (13) 13
genome-wide association study (13) 13
immunotherapy (13) 13
lung neoplasms - drug therapy (13) 13
neoplasm staging (12) 12
risk factors (12) 12
science & technology - other topics (12) 12
antineoplastic combined chemotherapy protocols - adverse effects (11) 11
lung cancer (11) 11
physiological aspects (11) 11
abridged index medicus (10) 10
clinical trials (10) 10
gene expression (10) 10
genetic predisposition to disease (10) 10
health aspects (10) 10
multidisciplinary sciences (10) 10
neoplasms - drug therapy (10) 10
prognosis (10) 10
treatment outcome (10) 10
antineoplastic combined chemotherapy protocols - therapeutic use (9) 9
cancer therapies (9) 9
general & internal medicine (9) 9
genes (9) 9
genetics & heredity (9) 9
hematology, oncology and palliative medicine (9) 9
lung cancer, non-small cell (9) 9
lung neoplasms - pathology (9) 9
metastases (9) 9
mutation (9) 9
pharmacology & pharmacy (9) 9
proteins (9) 9
young adult (9) 9
carcinoma, squamous cell - drug therapy (8) 8
cohort studies (8) 8
genetics (8) 8
medicine, general & internal (8) 8
mice (8) 8
physical sciences (8) 8
squamous cell carcinoma (8) 8
toxicity (8) 8
antibodies, monoclonal - administration & dosage (7) 7
antibodies, monoclonal - adverse effects (7) 7
antineoplastic agents - adverse effects (7) 7
biochemistry & molecular biology (7) 7
carcinoma, non-small-cell lung - pathology (7) 7
case-control studies (7) 7
follow-up studies (7) 7
lung neoplasms - genetics (7) 7
neoplasm recurrence, local - drug therapy (7) 7
pharmacology (7) 7
phenotype (7) 7
research article (7) 7
survival (7) 7
survival rate (7) 7
usage (7) 7
adenocarcinoma - genetics (6) 6
antibodies, monoclonal - therapeutic use (6) 6
antineoplastic agents (6) 6
antineoplastic combined chemotherapy protocols - pharmacokinetics (6) 6
apoptosis (6) 6
carcinoma, non-small-cell lung - genetics (6) 6
chromosomes (6) 6
disease control (6) 6
disease-free survival (6) 6
dose-response relationship, drug (6) 6
genetic loci (6) 6
genomics (6) 6
head and neck cancer (6) 6
maximum tolerated dose (6) 6
medicine (6) 6
medicine & public health (6) 6
medicine, experimental (6) 6
medicine, research & experimental (6) 6
neoplasm metastasis (6) 6
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Collection Dvlpm't (Acquisitions) - Vendor file (2) 2
OISE - Stacks (2) 2
Robarts - Stacks (2) 2
UofT at Mississauga - Stacks (2) 2
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Gerstein Science - Reference (1) 1
Gerstein Science - Stacks (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature medicine, ISSN 1546-170X, 10/2014, Volume 20, Issue 11, pp. 1301 - 1309
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2010, Volume 28, Issue 5, pp. 780 - 787
Journal Article
Journal Article
Nature (London), ISSN 1476-4687, 08/2011, Volume 477, Issue 7362, pp. 99 - 102
Journal Article
The New England journal of medicine, ISSN 1533-4406, 03/2014, Volume 370, Issue 13, pp. 1189 - 1197
Ceritinib is 20 times as potent as crizotinib at inhibiting anaplastic lymphoma kinase (ALK) in vitro. In patients, ceritinib produced antitumor responses in... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | Sulfones - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Young Adult | Recombination, Genetic | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | Carcinoma, Non-Small-Cell Lung - genetics | Pyrimidines - administration & dosage | Treatment Outcome | Sulfones - pharmacokinetics | Carcinoma, Non-Small-Cell Lung - mortality | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Maximum Tolerated Dose | Receptor Protein-Tyrosine Kinases - genetics | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Sulfones - administration & dosage | Antimitotic agents | Care and treatment | Dosage and administration | Research | Lung cancer, Non-small cell | Antineoplastic agents | Lung cancer | Diarrhea | Non-small cell lung carcinoma | Insulin-like growth factors | Dehydration | Kinases | Patients | Lymphoma | Gene amplification | Vomiting | Gene rearrangement | Hypophosphatemia | Antitumor activity | Mutation | Pharmaceutical industry | Protein-tyrosine kinase | Tumors | Index Medicus | Abridged Index Medicus
Journal Article